Trade Report: Today, Esperion Therapeutics Inc. (ESPR) Receives “Buy” Rating from JMP Securities

Today, Esperion Therapeutics Inc. (ESPR) Receives “Buy” Rating from JMP Securities

Esperion Therapeutics Inc. (NASDAQ:ESPR)‘s stock had its “buy” rating restated by research analysts at JMP Securities in a research note issued to investors on Sunday.

A number of other equities analysts also recently issued reports on ESPR. Vetr downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 target price for the company. in a research note on Monday, July 18th. Chardan Capital reissued a “neutral” rating and set a $12.50 target price on shares of Esperion Therapeutics in a research note on Saturday, October 15th. Zacks Investment Research downgraded Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 25th. Credit Suisse Group AG increased their target price on Esperion Therapeutics from $10.00 to $14.00 and gave the stock an “underperform” rating in a research note on Friday, October 14th. Finally, Barclays PLC set a $13.00 target price on Esperion Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, August 31st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $23.39.

Esperion Therapeutics (NASDAQ:ESPR) traded up 0.34% during trading on Friday, reaching $11.76. The company’s stock had a trading volume of 76,466 shares. The company’s market capitalization is $265.22 million. The company has a 50 day moving average price of $11.53 and a 200-day moving average price of $12.65. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $30.41.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.05. During the same period in the previous year, the company earned ($0.57) EPS. Equities research analysts anticipate that Esperion Therapeutics will post ($3.42) earnings per share for the current year.

In related news, COO Narendra D. Lalwani purchased 5,000 shares of the company’s stock in a transaction on Tuesday, November 1st. The stock was bought at an average price of $9.93 per share, with a total value of $49,650.00. Following the completion of the transaction, the chief operating officer now owns 5,000 shares of the company’s stock, valued at approximately $49,650. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 35.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Parametrica Management bought a new position in Esperion Therapeutics during the fourth quarter valued at $443,000. First Mercantile Trust Co. increased its position in Esperion Therapeutics by 23.2% in the fourth quarter. First Mercantile Trust Co. now owns 11,522 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 2,167 shares during the last quarter. Oxford Asset Management bought a new position in Esperion Therapeutics during the fourth quarter valued at $3,530,000. Columbus Circle Investors increased its position in Esperion Therapeutics by 42.7% in the fourth quarter. Columbus Circle Investors now owns 1,054,452 shares of the biopharmaceutical company’s stock valued at $23,472,000 after buying an additional 315,541 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in Esperion Therapeutics by 3.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 45,549 shares of the biopharmaceutical company’s stock valued at $1,014,000 after buying an additional 1,413 shares during the last quarter. 65.29% of the stock is owned by institutional investors.

About Esperion Therapeutics

Related posts

Leave a Comment